Is there a difference in outcome between stage I–II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer? Int J Radiat Oncol Biol Phys. 2002;54:79–85.Alektiar KM, McKee AB, Zelefsky MJ, et al. Is there a difference in outcome between stage I-II ...
Long-term Voice Outcome Following Radiation Versus Laser Microsurgery in Early Glottic Cancer There is no difference between the two groups in sex, age, stage, and follow-up time. Intraclass correlation coefficient between raters was high at 0.94... Y Ma,R Green,S Pan,... - 《Journal of ...
United States Health Policies and Late-stage Breast and colorectal cancer diagnosis: Why such disparities by age? Article Open access 15 July 2015 Data availability The data that support the findings of this study are available from Japan's Ministry of Health, Labour and Welfare (MHLW). Howev...
We do not know the exact timing of the death, only that it occurred between waves w − 1 and w. Where someone has been bereaved more than once, we included only the first bereavement as an event and continued to include the bereaved person’s outcomes in the analysis, to reflect the...
The DELTA2 (Difference ELicitation in TriAls) project comprised five major components: systematic literature reviews of recent methodological developments (stage 1) and existing funder guidance (stage 2); a Delphi study (stage 3); a two-day consensus meeting bringing together researchers, funders and...
A new company, veriNOS pharmaceuticals GmbH, of Wurzberg, Germany hopes to change all this with a late-stage drug candidate, ronopterin. If the name of the drug sounds familiar, that’s because it was previously developed by the biotech Vasopharm, which completed the late-stage phase 3 ...
Lane 1; stage 1, lane 2; stage 2, lane 3; stage 3, lane 4; stage 4, lane 5; stage 6. Proteomic changes of neuronal differentiated ES cells pH 5.5-6.7 500 µg of protein from the differentiated ES cells by time points was dehydrated using Immobilize Dry strip pH 5.5-6.7. Total ...
The discrepancies in the results between the present and earlier studies underscore the importance of replicating these analyses in different sample populations and in longitudinal studies. There were several differences between these 2 studies, including stage of disease, the anchor chosen, and the ...
and tumor suppressor genes, includingAKT2andKRAS. Using differentially regulated genes between healthy and tumor samples in conjunction with a drug repurposing tool, we identified several small-molecule drugs that might have sex-biased efficacy as cancer therapeutics and further validated this observation...
The harmony of clinical and pathological tumor stage was found in 62 cases and 38 patients were more advanced in pathological examination. In 62 cases the agreement between clinical and pathological N stage was found. In other 38 cases we found different N stage. In group with clinical enlarge...